Dr. Lukatch is Founder and Managing Partner of Red Tree Venture Capital, a life sciences venture capital firm. From 2015 to 2020, Dr. Lukatch worked at TPG where he was Partner, Managing Director and Life Sciences Investment Team Leader in TPG’s Biotech, Growth and RISE platforms. In 2006, Dr. Lukatch co-founded Novo Ventures’ San Francisco office, where he was a Partner through 2015. Prior to joining Novo Ventures, Dr. Lukatch was a Managing Director responsible for biotechnology venture investments at Piper Jaffray Ventures and SightLine Partners. Dr. Lukatch currently serves as Chairman of Engage Therapeutics, Inogen (INGN) and Satsuma Pharmaceuticals (STSA), and is a board member at Ceribell, Flexion (FLXN), Halo Neuroscience, Vaxcyte, ViaCyte and ViewPoint Therapeutics. Previously Dr. Lukatch was Chairman of Cianna Medical (acquired by Merit Medical) and Spinifex (acquired by Novartis), and served on multiple life sciences company boards, including: Amira (acquired by BMS), AnaptysBio (ANAB), Elevation Pharma (acquired by Sunovion), FoldRx (acquired by Pfizer), InSound Medical (acquired by Sonova) and Synosia Therapeutics (acquired by BioTie). Dr. Lukatch was also a board observer at Alios BioPharma (acquired by J&J), Dynavax (DVAX), Fluidigm (FLDM) and SI-Bone (SIBN). Prior to becoming an investor, Dr. Lukatch worked as a strategy consultant with McKinsey & Company and was co‐founder and CEO of AutoMate Scientific, a biotechnology instrumentation company. In addition, he was a bench scientist at Chiron, Roche Bioscience and Cetus, doing molecular biology, electrophysiology and protein chemistry, respectively. Dr. Lukatch received his PhD in Neuroscience from Stanford University where he was a DOD USAF Fellow, and his BA with high honors in Biochemistry from the University of California at Berkeley.
What is Heath Lukatch's net worth?
The estimated net worth of Heath Lukatch is at least $341,550.00 as of January 31st, 2024. Dr. Lukatch owns 5,625 shares of Vaxcyte stock worth more than $341,550 as of April 28th. This net worth evaluation does not reflect any other assets that Dr. Lukatch may own. Learn More about Heath Lukatch's net worth.
How do I contact Heath Lukatch?
Has Heath Lukatch been buying or selling shares of Vaxcyte?
Heath Lukatch has not been actively trading shares of Vaxcyte within the last three months. Most recently, Heath Lukatch sold 5,000 shares of the business's stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $71.50, for a transaction totalling $357,500.00. Following the completion of the sale, the director now directly owns 5,625 shares of the company's stock, valued at $402,187.50. Learn More on Heath Lukatch's trading history.
Who are Vaxcyte's active insiders?
Are insiders buying or selling shares of Vaxcyte?
In the last year, insiders at the sold shares 33 times. They sold a total of 281,096 shares worth more than $16,832,337.62. The most recent insider tranaction occured on April, 23rd when CEO Grant Pickering sold 15,000 shares worth more than $928,800.00. Insiders at Vaxcyte own 3.6% of the company.
Learn More about insider trades at Vaxcyte. Information on this page was last updated on 4/23/2024.
